About ACA Pharma
From Zero to
Asia, Faster
ACA Pharma helps innovative medicines and devices reach patients faster—starting with Macau and Hong Kong fast-track pathways, then bridging into Mainland China and other key markets through compliant, end-to-end commercialization.
Learn More
Who We Are
ACA Pharma is a U.S.-headquartered, licensed partner built to help innovative medicines and medical devices reach patients faster across Asia. We're a single, easy party to contract with and operate through established, licensed entities with teams, warehouses and on-the-ground personnel across Macau, Hong Kong, Singapore, and Mainland China, with on-the-ground sales coverage reaching every province.
Speed to Market
- FDA, EMA, MHRA referenced registrations
- Medicines: 30-90 days Macau approval
- Devices: ~3 month Hong Kong approval
- Bridge into Mainland China pilot zones
- RWE supports accelerated national approval
End-to-End Execution
- Registration through launch
- Import permits & logistics
- Expert, KOL-driven promotion
- Key Mailand SOE partnerships
- Commercial scale-up after entry
Asset-Light Model
- No upfront build-out
- We fund local execution
- Partners supply product
- Partners retain all IP
- Our costs recovered post-launch
What Inspires Us
Innovation only matters when patients can reach it. We’re motivated by the gap we see every day—clinically important therapies available elsewhere, while families wait. ACA Pharma exists to close that gap by compressing time-to-access across Asia through Macau and Hong Kong fast-track entry points and pilot-zone pathways, while supporting broader expansion across other key global markets using reference-based approvals and practical, execution-first commercialization.
The Fastest Way to Market — Done Right.
Our Asia-based teams — from Macau to Hong Kong, Singapore and across Mainland China — operate as an extension of your organization, built for speed and hospital execution. We’ve delivered 100+ Macau fast-track registrations in two years and lead market volume (~80% share), reflecting deep regulator trust and a process that works repeatedly. We fund and run the in-market work end-to-end, while partners retain IP and focus on supplying product — an asset-light model aligned to performance.
Asia Market Entry Specialists
On-the-ground execution, broader reach
We support rare-disease programs across therapeutic areas, from early access to multi-country expansion beyond China
